Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
      Immunologic Memory*; Antigens, Bacterial/*immunology ; B-Lymphocytes/*immunology ; Enterotoxigenic Escherichia coli/*immunology ; Escherichia coli Infections/*immunology; Adult ; Antibodies, Bacterial/immunology ; Antibody Affinity ; Bacterial Toxins/immunology ; Bangladesh ; Enterotoxins/immunology ; Escherichia coli Proteins/immunology ; Female ; Fimbriae Proteins/immunology ; Humans ; Immunoglobulin A/immunology ; Immunoglobulin G/immunology ; Male
    • نبذة مختصرة :
      Background: Multiple infections with diverse enterotoxigenic E. coli (ETEC) strains lead to broad spectrum protection against ETEC diarrhea. However, the precise mechanism of protection against ETEC infection is still unknown. Therefore, memory B cell responses and affinity maturation of antibodies to the specific ETEC antigens might be important to understand the mechanism of protection.
      Methodology: In this study, we investigated the heat labile toxin B subunit (LTB) and colonization factor antigens (CFA/I and CS6) specific IgA and IgG memory B cell responses in Bangladeshi adults (n = 52) who were infected with ETEC. We also investigated the avidity of IgA and IgG antibodies that developed after infection to these antigens.
      Principal Findings: Patients infected with ETEC expressing LT or LT+heat stable toxin (ST) and CFA/I group or CS6 colonization factors developed LTB, CFA/I or CS6 specific memory B cell responses at day 30 after infection. Similarly, these patients developed high avidity IgA and IgG antibodies to LTB, CFA/I or CS6 at day 7 that remained significantly elevated at day 30 when compared to the avidity of these specific antibodies at the acute stage of infection (day 2). The memory B cell responses, antibody avidity and other immune responses to CFA/I not only developed in patients infected with ETEC expressing CFA/I but also in those infected with ETEC expressing CFA/I cross-reacting epitopes. We also detected a significant positive correlation of LTB, CFA/I and CS6 specific memory B cell responses with the corresponding increase in antibody avidity.
      Conclusion: This study demonstrates that natural infection with ETEC induces memory B cells and high avidity antibodies to LTB and colonization factor CFA/I and CS6 antigens that could mediate anamnestic responses on re-exposure to ETEC and may help in understanding the requirements to design an effective vaccination strategies.
    • References:
      Infect Immun. 1988 Feb;56(2):523-8. (PMID: 3276628)
      Clin Diagn Lab Immunol. 2001 Mar;8(2):424-8. (PMID: 11238232)
      Clin Vaccine Immunol. 2013 Jan;20(1):17-23. (PMID: 23114701)
      PLoS One. 2009;4(2):e4487. (PMID: 19242561)
      Clin Vaccine Immunol. 2012 May;19(5):690-8. (PMID: 22441386)
      Viral Immunol. 2008 Mar;21(1):3-11. (PMID: 18355118)
      Infect Immun. 1994 Oct;62(10):4339-46. (PMID: 7927693)
      Infect Immun. 1998 Jul;66(7):3311-6. (PMID: 9632600)
      Clin Vaccine Immunol. 2012 Dec;19(12):1921-31. (PMID: 23035175)
      Immunity. 2007 Aug;27(2):190-202. (PMID: 17723214)
      J Immunol Methods. 2004 Mar;286(1-2):111-22. (PMID: 15087226)
      Infect Immun. 2007 May;75(5):2269-74. (PMID: 17296752)
      Epidemiol Infect. 1997 Dec;119(3):391-3. (PMID: 9440444)
      Vaccine. 2006 Feb 27;24(9):1359-66. (PMID: 16233937)
      Infect Immun. 1982 Oct;38(1):74-9. (PMID: 6754618)
      Appl Microbiol Biotechnol. 2012 Mar;93(6):2291-300. (PMID: 22350259)
      PLoS Negl Trop Dis. 2011 Apr 05;5(4):e999. (PMID: 21483709)
      Adv Exp Med Biol. 1995;371B:1623-8. (PMID: 7502870)
      Infect Immun. 2002 Mar;70(3):1056-68. (PMID: 11854183)
      Clin Microbiol Rev. 2005 Jul;18(3):465-83. (PMID: 16020685)
      FEMS Microbiol Lett. 1989 Oct 1;52(1-2):105-8. (PMID: 2574694)
      Vaccine. 2013 May 7;31(20):2457-64. (PMID: 23541621)
      Infect Immun. 2006 Jun;74(6):3488-97. (PMID: 16714580)
      Microb Pathog. 1994 Feb;16(2):131-9. (PMID: 8047001)
      Annu Rev Immunol. 2011;29:621-63. (PMID: 21314428)
      Trends Microbiol. 1996 Nov;4(11):444-52. (PMID: 8950814)
      Expert Rev Vaccines. 2012 Apr;11(4):407-9. (PMID: 22551024)
      Lancet. 1990 Apr 21;335(8695):958-61. (PMID: 1970034)
      Vaccine. 2013 Feb 6;31(8):1163-70. (PMID: 23306362)
      Am J Trop Med Hyg. 2008 Nov;79(5):708-14. (PMID: 18981509)
      Semin Immunol. 2004 Oct;16(5):323-33. (PMID: 15528077)
      Infect Immun. 2009 Sep;77(9):3850-6. (PMID: 19528207)
      J Health Popul Nutr. 2004 Dec;22(4):370-82. (PMID: 15663170)
      Infect Immun. 2006 Aug;74(8):4512-8. (PMID: 16861637)
      Infect Immun. 1990 Feb;58(2):341-6. (PMID: 1967593)
      Expert Rev Mol Med. 2002 Oct 01;4(21):1-16. (PMID: 14585161)
      Expert Rev Vaccines. 2012 Apr;11(4):495-507. (PMID: 22551034)
      Clin Vaccine Immunol. 2011 May;18(5):844-50. (PMID: 21346055)
      J Travel Med. 2005 Mar-Apr;12(2):102-7. (PMID: 15996455)
      Appl Microbiol Biotechnol. 2010 Jul;87(4):1355-65. (PMID: 20405124)
      Infect Immun. 2004 Dec;72(12):7190-201. (PMID: 15557644)
      Vaccine. 2007 May 30;25(22):4392-400. (PMID: 17448578)
      Indian J Med Res. 2011 Feb;133:188-96. (PMID: 21415493)
      Curr Opin Immunol. 2005 Aug;17(4):388-98. (PMID: 15963708)
      Infect Immun. 2007 Aug;75(8):3961-8. (PMID: 17548483)
    • Grant Information:
      AI106878 United States AI NIAID NIH HHS; TW005572 United States TW FIC NIH HHS; R01 AI106878 United States AI NIAID NIH HHS; U01 AI077883 United States AI NIAID NIH HHS; AI058935 United States AI NIAID NIH HHS; U01 AI058935 United States AI NIAID NIH HHS; AI077883 United States AI NIAID NIH HHS; D43 TW005572 United States TW FIC NIH HHS; R56 AI106878 United States AI NIAID NIH HHS; R37 AI106878 United States AI NIAID NIH HHS
    • الرقم المعرف:
      0 (Antibodies, Bacterial)
      0 (Antigens, Bacterial)
      0 (Bacterial Toxins)
      0 (CS6 antigen, E coli)
      0 (Enterotoxins)
      0 (Escherichia coli Proteins)
      0 (Immunoglobulin A)
      0 (Immunoglobulin G)
      147680-16-8 (Fimbriae Proteins)
      D9K3SN2LNY (heat-labile enterotoxin, E coli)
    • الموضوع:
      Date Created: 20140426 Date Completed: 20141030 Latest Revision: 20211216
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC3998937
    • الرقم المعرف:
      10.1371/journal.pntd.0002822
    • الرقم المعرف:
      24762744